T

Tarsus Pharmaceuticals

Develops FDA-approved ophthalmic therapies

Regional Director - Field Medical Affairs, East

Full-TimeUpdated on 10/23/2026
$203.2k - $284.6k+ Bonus + Stock equity
Expert
PharmD, PhD, MD
Irvine, CA, USA
RemotePrimarily remote; approximately 50–75% travel for KOL engagement, field rides, scientific meetings, and team management.
Biology & Biotech

About the job

Requirements
  • An OD, PhD, PharmD, MD, or other advanced degree in a relevant scientific discipline, with experience in eye care.
  • At least 10 years of experience in Medical Affairs or related scientific roles, including at least 5 years of leadership experience managing a team of Medical Science Liaisons.
  • A proven track record of building relationships with key opinion leaders, eye care practitioners, and key medical-community stakeholders.
  • Experience working in cross-functional teams and collaborating effectively with commercial, clinical, regulatory, and other business functions.
  • Strong leadership skills and the ability to inspire, motivate, and collaborate cross-functionally.
Responsibilities
  • Lead, mentor, and manage a team of six Medical Science Liaisons, fostering a collaborative, high-performing, scientifically rigorous culture.
  • Set expectations for each Medical Science Liaison’s territory plans, objectives, and key performance indicators.
  • Conduct performance evaluations, identify skill gaps, and support Medical Science Liaison development through coaching, training, and career-growth opportunities.
  • Collaborate with Medical Affairs Operations leadership to align Medical Science Liaison activities with organizational priorities and strategic initiatives.
  • Serve as a disease-state and product expert, providing strategic input into Medical Science Liaison educational initiatives and product-launch planning.
  • Contribute to Field Medical Strategy and Tactics in alignment with corporate and medical strategic goals.
  • Ensure Medical Science Liaisons have current scientific data and clinical information and support their integration into regional and national initiatives.
  • Partner with Medical Affairs Strategy Leads to oversee the Medical Strategy Tactical Team, synthesizing medical-affairs insights into actionable plans.
  • Collaborate with the Field Medical Trainer and Medical Operations Leadership to develop and participate in field medical training and serve as a resource for the field team.
  • Support medical-conference strategy and planning, attend conferences, provide scientific expertise, and collaborate with eye care practitioners.
  • Identify gaps in eye care practitioner education and clinical evidence, propose ways to address unmet educational and evidence needs, and collaborate with medical experts on disease-state and product-related education.
  • Provide strategic oversight of Medical Science Liaison engagement with key opinion leaders, eye care practitioners, clinician scientists, researchers, and regional stakeholders to ensure consistent, high-quality scientific exchange.
  • Oversee team participation in scientific congresses, advisory boards, and other external engagements to strengthen relationships and advance scientific understanding.
  • Stay current on scientific literature and the market, and track key opinion leader engagement and opportunities for disease-state education and awareness.
  • Oversee team compliance with pharmacovigilance and safety requirements, including accurate and timely adverse-event reporting.
  • Partner compliantly with regional Sales leadership on field-related needs and solutions.
  • Ensure Medical Science Liaison activities comply with regulatory, ethical, and company standards, including Good Clinical Practice and HIPAA regulations.
  • Provide regular updates to the Medical Affairs Vice President and Operations on team progress, key opinion leader engagement, initiatives, impact metrics, outcomes, feedback, opportunities, and potential solutions.
  • Monitor the competitive landscape and emerging ophthalmology trends, ensuring Medical Science Liaison activities reflect current scientific advances.
  • Travel approximately 50–75% for key opinion leader engagement, field rides, scientific meetings, and team-management activities.
Desired Qualifications
  • In-depth knowledge of eye care, ophthalmology, or optometry.
  • Previous experience leading a Field Medical Team within a biopharmaceutical company.

About the company

Tarsus Pharmaceuticals develops and markets treatments for eye care and infectious diseases, including XDEMVY, an FDA-approved lotilaner eye drop for Demodex Blepharitis. It works by applying the ophthalmic solution to the eyelids to kill Demodex mites and reduce eyelid inflammation. The company differentiates itself with a focused ocular and infectious diseases portfolio and by pursuing collaborations to advance its pipeline alongside selling approved products. Its goal is to address unmet medical needs, grow its product lineup, and expand into additional indications in eye care and infectious diseases.

Company Size

201-500

Company Stage

IPO

Headquarters

Irvine, California

Founded

2017

Get referred to Tarsus Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 XDEMVY sales hit $173.9 million, up 69% year over year.
  • Management raised 2026 XDEMVY guidance to $685 million-$705 million.
  • Cash reached $449.7 million on June 30, 2026, supporting launches and trials.

What critics are saying

  • XDEMVY revenue concentration leaves Tarsus exposed if prescribing slows in 2027.
  • ALK-001’s NORTHSTAR Phase 3 reads out only in second half 2029.
  • Alkeus adds $450 million upfront; integration failure can crush 2027 profitability.

What makes Tarsus Pharmaceuticals unique

  • XDEMVY became the first FDA-approved Demodex blepharitis therapy in 2023.
  • August 2026 Alkeus acquisition adds ALK-001, expanding Tarsus into retina.
  • Tarsus monetizes lotilaner globally; Grand Pharma paid a $15 million China milestone.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Paid Vacation
  • Hybrid Work Options
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

1%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 7th, 2026
Tarsus raises 2026 XDEMVY sales outlook to $705M, acquires Alkeus for $450M upfront

Tarsus Pharmaceuticals reported strong Q2 performance for its Demodex blepharitis treatment XDEMVY, with sales rising 69% year-over-year to $173.9 million. The company raised its 2026 sales guidance to $685–$705 million, noting that over 700,000 patients have used the treatment since launch. Tarsus announced plans to acquire Alkeus Pharmaceuticals for $450 million upfront, adding late-stage Stargardt disease therapy ALK-001 to its pipeline. The Phase III NORTHSTAR trial is underway, with top-line results expected in the second half of 2029. The acquisition will expand Tarsus' strategy beyond XDEMVY into retina care. However, the company raised 2026 R&D guidance to $190–$210 million due to increased near-term spending. Profitability could potentially arrive in 2027, subject to acquisition-related costs.

Vision Monday
Aug 7th, 2026
Tarsus to acquire Alkeus in $450 million deal, reports strong Quarter and half.

Tarsus to acquire Alkeus in $450 million deal, reports strong Quarter and half. Friday, August 7, 2026 12:24 AM IRVINE, Calif. - Tarsus Pharmaceuticals announced yesterday that it has entered into a definitive agreement to acquire Alkeus Pharmaceuticals, Inc., a privately held retinal disease-focused biotechnology company developing gildeuretinol (ALK-001), an investigational once-daily oral therapy for Stargardt disease. The deal includes an upfront consideration of about $450 million, the companies said, comprising $270 million in cash and $180 million in Tarsus common stock. The pending transaction is expected to close this year, and also includes a milestone of up to $350 million upon potential regulatory approval and first commercial sale. The news was announced along with a strong unaudited financial report that saw total Q2 revenue for Tarsus rise to $173.9 million and first half revenue rise to nearly $336 million. According to the announcement, the planned acquisition of Alkeus represents what Tarsus said is an important step in its long-term strategy to build a leading eyecare company by bringing differentiated medicines to patients with significant unmet needs. The acquisition is expected to expand Tarsus' growing presence in retina, complement the capabilities established through the acquisition of iRenix Medical last month, and add a differentiated phase 3 program potentially addressing Stargardt disease. "From the beginning, our strategy has been to build a leading eyecare company by identifying significant diseases where patients have been starving for innovation and bringing forward medicines with the potential to change the standard of care," said Bobby Azamian, MD, Ph.D., CEO and chairman of Tarsus. "We believe gildeuretinol has the potential to be a transformational medicine for Stargardt disease and complements the retina capabilities we are already building through IRX-101. We also have tremendous respect for the Alkeus team and the exceptional work they have done to identify and bring forward an optimal asset to potentially address this blinding disease." Second Quarter and First Half Reporting The acquisition announcement came nearly concurrent with strong unaudited second quarter and first half reporting from Tarsus. Net sales of $173.9 million marked more than 69 percent growth versus last year's Q2 of $102.7 million, with net product sales of XDEMVY (lotilaner ophthalmic solution) 0.25%, a prescription eye drop designed to treat Demodex blepharitis, serving as a primary revenue driver, as well as what the company said was higher volume and improvements in the gross-to-net discount. Total first-half revenue for the company was reported at nearly $336 million (versus $181 million for the same period last year), with $319.3 million attributed to XDEMVY product sales and $16.7 million attributed to license fees and collaborations. Cost of sales in Q2 were $12.1 million compared with $6.2 million for the same period in 2025, due to manufacturing costs related to Xdemvy, the company said. Research and development expenses totaled $31.0 million compared with $15.6 million for the same period in 2025. Selling, general and administrative expenses were $150.7 million compared with $103.0 million for the same period in 2025. Net loss in the second quarter narrowed to $18.6 million, compared with $20.3 million for the same period in 2025, the company said. As of June 30, 2026, cash, cash equivalents and marketable securities were $449.7 million. The company also took the further step of increasing 2026 net sales guidance for XDEMVY to $685 million to $705 million. Related to the pending acquisition, Barclays is acting as exclusive financial advisor to Tarsus and Jefferies is acting as exclusive financial advisor to Alkeus. Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP is acting as legal counsel to Tarsus, and Latham & Watkins LLP is acting as legal counsel to Alkeus.

Central Charts
Aug 6th, 2026
Tarsus Pharmaceuticals raises $125M in oversubscribed PIPE financing to fund Alkeus acquisition

Tarsus Pharmaceuticals has secured $125 million through an oversubscribed private placement equity financing. The transaction includes participation from investors in Alkeus Pharmaceuticals, which Tarsus announced it would acquire earlier the same day. Notable investors include TCGX, Bain Capital Life Sciences, Wellington Management, ADAR1 Capital Management, Sirenia Capital Management LP, RTW Investments, and Vestal Point Capital. The company is selling 2,098,519 shares of common stock at $56 per share and pre-funded warrants to purchase 133,625 additional shares. The financing is expected to close on 7 August 2026. Tarsus intends to use the proceeds to fund clinical development, commercial activities, and general corporate purposes. Barclays is serving as lead placement agent, with BofA Securities and William Blair as co-placement agents.

GlobeNewswire
Aug 6th, 2026
Tarsus Pharmaceuticals acquires Alkeus for $450M to advance Stargardt disease treatment

Tarsus Pharmaceuticals has agreed to acquire Alkeus Pharmaceuticals for approximately $450 million upfront, consisting of $270 million in cash and $180 million in Tarsus stock. The deal includes potential milestone payments of up to $350 million upon regulatory approval and first commercial sale, plus low single-digit royalties. The acquisition adds gildeuretinol (ALK-001), a Phase 3 oral investigational medicine for Stargardt disease, an inherited retinal condition affecting over 36,000 people in the US with no FDA-approved treatments. More than 400 individuals have been treated with the drug to date, showing encouraging clinical findings. Top-line Phase 3 NORTHSTAR data are expected in the second half of 2029. The transaction has been approved by both companies' boards and Alkeus stockholders. It is expected to close in 2026, subject to regulatory clearances and customary conditions.

Minichart
Jul 9th, 2026
Tarsus Pharmaceuticals Acquires iRenix Medical to Advance Eye Care with Late-Stage IRX-101 Asset

Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) has announced a major strategic acquisition, taking over privately held iRenix Medical, Inc., a clinical-stage ophthalmic biopharmaceutical company. This transaction marks a significant step in Tarsus’ ambition to expand its leadership in the eye care market and could have material implications for the company’s future growth, pipeline development, and share price.